{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": "Liu_et_al.__2024_",
  "verified_evidence": [
    {
      "id": 2,
      "quote": "After vaccination, in both age groups, the two egg based vaccines generally reinforced the neutralizing antibody responses to egg adapted epitopes as evidenced by an increased trend in the proportion of participants with GMT egg cell titer ratio \u22654. In contrast, among RIV4 and ccIIV4 recipients, the proportion of participants with GMT egg cell titer ratio \u22654 was significantly lower, suggesting that non egg based vaccines induced a broader antibody response to both egg and cell propagated viruses.",
      "supports_claim": true,
      "explanation": "The quote appears on page 5 of the document, with only minor differences in wording but identical factual content. The relevant passage is: 'After vaccination, in both age groups, the two egg based vaccines generally reinforced the neutralizing antibody responses to egg adapted epi to pes as evidenced by an increased trend in the proportion of participants with GMT egg cell titer ratio \u22654. In contrast, among RIV4 and ccIIV4 recipients, the proportion of participants with GMT egg cell titer ratio \u22654 was significantly lower, suggesting that non egg based vaccines induced a broader antibody response to both egg and cell propagated viruses.' This matches the quote to verify in all substantive details.. The quote directly supports the claim. It states that non-egg-based vaccines (including recombinant RIV4) induced a broader antibody response to both egg and cell propagated viruses, as opposed to egg-based vaccines, which reinforced a narrower, egg-adapted response. This broader response is relevant to the claim that recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season. The quote provides explicit comparative immunogenicity data supporting the claim.",
      "presence_explanation": "The quote appears on page 5 of the document, with only minor differences in wording but identical factual content. The relevant passage is: 'After vaccination, in both age groups, the two egg based vaccines generally reinforced the neutralizing antibody responses to egg adapted epi to pes as evidenced by an increased trend in the proportion of participants with GMT egg cell titer ratio \u22654. In contrast, among RIV4 and ccIIV4 recipients, the proportion of participants with GMT egg cell titer ratio \u22654 was significantly lower, suggesting that non egg based vaccines induced a broader antibody response to both egg and cell propagated viruses.' This matches the quote to verify in all substantive details.",
      "support_explanation": "The quote directly supports the claim. It states that non-egg-based vaccines (including recombinant RIV4) induced a broader antibody response to both egg and cell propagated viruses, as opposed to egg-based vaccines, which reinforced a narrower, egg-adapted response. This broader response is relevant to the claim that recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season. The quote provides explicit comparative immunogenicity data supporting the claim.",
      "original_relevance": "This quote directly compares the immune response profiles, showing that recombinant (and cell-based) vaccines avoid the narrow, egg-adapted response and instead induce broader immunity, which is relevant for cross-protection in mismatch seasons."
    },
    {
      "id": 5,
      "quote": "The potential of non egg based vaccines to mitigate the impact of prior egg based vaccination remains unclear. In this study, repeat vaccination with either RIV4 or ccIIV4 further improved antibody responses to circulating viruses compared to repeated egg based vaccination.",
      "supports_claim": true,
      "explanation": "The quote appears in the document, though with minor formatting and word order differences due to OCR cleanup. The relevant passage is: 'The potential of non egg based vaccines to miti gate the impact of prior egg based a cci nation remains nclear In this study, repeat vaccination with either RIV4 or ccIIV4 further improved antibody responses to circulating iith d d tli itib d / ll ti RIV4 l h d...' This matches the quoted content in meaning and technical detail, specifically stating that repeat vaccination with recombinant (RIV4) or cell-based (ccIIV4) vaccines improved antibody responses to circulating viruses compared to repeated egg-based vaccination.. The quote directly supports the claim. It states that repeat vaccination with recombinant (RIV4) or cell-based (ccIIV4) vaccines 'further improved antibody responses to circulating viruses compared to repeated egg based vaccination.' This is explicit evidence that recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season, as it shows improved responses to circulating (potentially mismatched) viruses.",
      "presence_explanation": "The quote appears in the document, though with minor formatting and word order differences due to OCR cleanup. The relevant passage is: 'The potential of non egg based vaccines to miti gate the impact of prior egg based a cci nation remains nclear In this study, repeat vaccination with either RIV4 or ccIIV4 further improved antibody responses to circulating iith d d tli itib d / ll ti RIV4 l h d...' This matches the quoted content in meaning and technical detail, specifically stating that repeat vaccination with recombinant (RIV4) or cell-based (ccIIV4) vaccines improved antibody responses to circulating viruses compared to repeated egg-based vaccination.",
      "support_explanation": "The quote directly supports the claim. It states that repeat vaccination with recombinant (RIV4) or cell-based (ccIIV4) vaccines 'further improved antibody responses to circulating viruses compared to repeated egg based vaccination.' This is explicit evidence that recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season, as it shows improved responses to circulating (potentially mismatched) viruses.",
      "original_relevance": "This quote provides direct evidence that recombinant (and cell-based) vaccines enhance immune responses to circulating (i.e., potentially mismatched) viruses, supporting the claim of broader and cross-protective immunity."
    },
    {
      "id": "comp_1",
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.",
      "supports_claim": true,
      "explanation": "The quote 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' appears in the document, almost verbatim, in the following sentence: 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' This is found in the first long paragraph of the document, and the factual content, numbers, and technical details are preserved.. The quote directly supports the claim that recombinant technology (RIV4) leads to a broader immune response that may provide cross-protection, even in a mismatch season. The quote explicitly states that RIV4 induced higher neutralizing and total HA head binding antibodies to the cell-propagated (wild-type-like) A (H3 N2) virus compared to the other vaccines. Since cell-propagated viruses are more similar to circulating strains than egg-adapted ones, this demonstrates that RIV4 elicits a stronger and potentially broader immune response, supporting the claim without requiring inference beyond what is stated.",
      "presence_explanation": "The quote 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' appears in the document, almost verbatim, in the following sentence: 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' This is found in the first long paragraph of the document, and the factual content, numbers, and technical details are preserved.",
      "support_explanation": "The quote directly supports the claim that recombinant technology (RIV4) leads to a broader immune response that may provide cross-protection, even in a mismatch season. The quote explicitly states that RIV4 induced higher neutralizing and total HA head binding antibodies to the cell-propagated (wild-type-like) A (H3 N2) virus compared to the other vaccines. Since cell-propagated viruses are more similar to circulating strains than egg-adapted ones, this demonstrates that RIV4 elicits a stronger and potentially broader immune response, supporting the claim without requiring inference beyond what is stated.",
      "original_relevance": "This quote shows that the recombinant vaccine (RIV4) generated higher levels of neutralizing and binding antibodies to the cell-propagated (wild-type-like) H3N2 virus, supporting the claim that recombinant technology leads to a broader immune response that may provide cross-protection, especially in seasons where the circulating virus differs from the egg-adapted vaccine strain."
    },
    {
      "id": "comp_2",
      "quote": "RIV4 contains 3 times the i d 45 HA/d / ...d IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody ... it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).",
      "supports_claim": true,
      "explanation": "The quote appears on page 9 of the document, with only minor formatting differences and some OCR artifacts in the original. The key factual content is present: 'RIV4 contains 3 times the ... HA/d ... IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody ... it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).' The numbers and technical content match the quote to verify.. The quote directly supports the claim. It states that RIV4 (the recombinant vaccine) not only improved the quality of the functional neutralizing antibody but also significantly increased the quantity of total A (H3 N2) cell HA head binding antibodies compared to IIV4 and ccIIV4. Since cell-propagated H3N2 is more representative of circulating strains, this demonstrates a broader immune response, which is the basis for potential cross-protection even in a mismatch season. The quote provides specific data and a direct comparison, explicitly supporting the claim.",
      "presence_explanation": "The quote appears on page 9 of the document, with only minor formatting differences and some OCR artifacts in the original. The key factual content is present: 'RIV4 contains 3 times the ... HA/d ... IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody ... it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).' The numbers and technical content match the quote to verify.",
      "support_explanation": "The quote directly supports the claim. It states that RIV4 (the recombinant vaccine) not only improved the quality of the functional neutralizing antibody but also significantly increased the quantity of total A (H3 N2) cell HA head binding antibodies compared to IIV4 and ccIIV4. Since cell-propagated H3N2 is more representative of circulating strains, this demonstrates a broader immune response, which is the basis for potential cross-protection even in a mismatch season. The quote provides specific data and a direct comparison, explicitly supporting the claim.",
      "original_relevance": "This quote indicates that the recombinant vaccine (RIV4) not only improved the quality but also the quantity of antibodies against the cell-propagated H3N2 virus, which is more representative of circulating strains, thus supporting a broader and potentially cross-protective immune response."
    }
  ],
  "verification_stats": {
    "total_verified": 4
  },
  "image_evidence": [
    {
      "image_filename": "figure_p5_det_4_000.png",
      "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p5_det_4_000.png",
      "image_type": "Figure",
      "page_number": 5,
      "block_id": "det_4_000",
      "claim_id": "claim_003",
      "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
      "supports_claim": true,
      "explanation": "Four-panel figure showing geometric mean fold-rise of MN or HI antibody titers at 1 month post-vaccination (panels A, B) and fold-reduction of titers at 6 months (panels C, D) in two age cohorts (18\u201344 years and 45\u201364 years). Data are shown for four vaccines: FluZone IIV4 (egg-based), FluArix IIV4 (egg-based), ccIIV4 (cell-based), and RIV4 (recombinant). For each vaccine, titers are measured against egg-propagated and cell-propagated H3N2, H1N1, B/Victoria lineage, and B/Yamagata lineage viruses, with p-values comparing RIV4 to other vaccines. Evidence: In both age groups, RIV4 (recombinant) induced significantly higher fold-rise in antibody titers against cell-propagated H3N2 (p<0.0001) and H1N1 egg or cell antigens compared to egg-based vaccines, indicating enhanced immunogenicity to wild-type (cell-propagated) strains. The figure shows that the recombinant vaccine (RIV4) elicits higher antibody responses against cell-propagated (i.e., wild-type) influenza strains compared to egg-based vaccines, demonstrating a broader immune response that supports the claim. Note: Immunogenicity data are presented; clinical protection in mismatch seasons is inferred but not directly measured in this figure.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "Four-panel figure showing geometric mean fold-rise of MN or HI antibody titers at 1 month post-vaccination (panels A, B) and fold-reduction of titers at 6 months (panels C, D) in two age cohorts (18\u201344 years and 45\u201364 years). Data are shown for four vaccines: FluZone IIV4 (egg-based), FluArix IIV4 (egg-based), ccIIV4 (cell-based), and RIV4 (recombinant). For each vaccine, titers are measured against egg-propagated and cell-propagated H3N2, H1N1, B/Victoria lineage, and B/Yamagata lineage viruses, with p-values comparing RIV4 to other vaccines.",
        "evidence_found": "In both age groups, RIV4 (recombinant) induced significantly higher fold-rise in antibody titers against cell-propagated H3N2 (p<0.0001) and H1N1 egg or cell antigens compared to egg-based vaccines, indicating enhanced immunogenicity to wild-type (cell-propagated) strains.",
        "reasoning": "The figure shows that the recombinant vaccine (RIV4) elicits higher antibody responses against cell-propagated (i.e., wild-type) influenza strains compared to egg-based vaccines, demonstrating a broader immune response that supports the claim.",
        "confidence_notes": "Immunogenicity data are presented; clinical protection in mismatch seasons is inferred but not directly measured in this figure."
      }
    },
    {
      "image_filename": "figure_p6_det_5_006.png",
      "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p6_det_5_006.png",
      "image_type": "Figure",
      "page_number": 6,
      "block_id": "det_5_006",
      "claim_id": "claim_003",
      "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
      "supports_claim": true,
      "explanation": "Figure 4 presents ELISA-measured HA head (egg\u2010 and cell\u2010derived HA, Panel A) and HA stalk (Panels C and D) antibody responses at pre\u2010vaccination (Day 0), 1 month, and 6 months after vaccination for four vaccine groups: two egg-based IIV4s (Fluzone and FluLaval), a cell-culture IIV4 (ccIIV4), and a recombinant HA vaccine (RIV4). Panel B shows the ratio of egg- to cell-derived HA head binding titers at 1 month. Grey dots indicate individual titers; colored bars and error bars indicate geometric mean titers (GMTs) with 95% CIs. Statistical comparisons (p-values) are annotated. Evidence: In Panels C and D, the RIV4 (recombinant) group exhibits significantly higher H3 and H1 stalk antibody GMTs and fold\u2010rise at 1 month compared to the egg-based vaccines, indicating enhanced induction of stalk\u2010directed (conserved) antibodies. The elevated HA stalk antibody responses elicited by the recombinant RIV4 vaccine, as shown in Panels C and D, support the claim that recombinant technology leads to a broader immune response; stalk antibodies target conserved regions and are associated with potential cross-protection, even in mismatch seasons, so this immunogenicity data supports the claim. Note: The figure demonstrates immunogenicity (stalk antibody levels) but does not directly measure clinical cross-protection or efficacy in a mismatch season; results are surrogate markers.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "Figure 4 presents ELISA-measured HA head (egg\u2010 and cell\u2010derived HA, Panel A) and HA stalk (Panels C and D) antibody responses at pre\u2010vaccination (Day 0), 1 month, and 6 months after vaccination for four vaccine groups: two egg-based IIV4s (Fluzone and FluLaval), a cell-culture IIV4 (ccIIV4), and a recombinant HA vaccine (RIV4). Panel B shows the ratio of egg- to cell-derived HA head binding titers at 1 month. Grey dots indicate individual titers; colored bars and error bars indicate geometric mean titers (GMTs) with 95% CIs. Statistical comparisons (p-values) are annotated.",
        "evidence_found": "In Panels C and D, the RIV4 (recombinant) group exhibits significantly higher H3 and H1 stalk antibody GMTs and fold\u2010rise at 1 month compared to the egg-based vaccines, indicating enhanced induction of stalk\u2010directed (conserved) antibodies.",
        "reasoning": "The elevated HA stalk antibody responses elicited by the recombinant RIV4 vaccine, as shown in Panels C and D, support the claim that recombinant technology leads to a broader immune response; stalk antibodies target conserved regions and are associated with potential cross-protection, even in mismatch seasons, so this immunogenicity data supports the claim.",
        "confidence_notes": "The figure demonstrates immunogenicity (stalk antibody levels) but does not directly measure clinical cross-protection or efficacy in a mismatch season; results are surrogate markers."
      }
    },
    {
      "image_filename": "figure_p7_mrg_det_6_003.png",
      "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p7_mrg_det_6_003.png",
      "image_type": "Figure",
      "page_number": 7,
      "block_id": "mrg_det_6_003",
      "claim_id": "claim_003",
      "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
      "supports_claim": true,
      "explanation": "Four\u2010panel figure showing serologic comparisons among four influenza vaccines (Fluzone IIV4, Fluarix IIV4, ccIIV4, RIV4) in two age groups (18\u201344 years in panels A and C, 45\u201364 years in panels B and D). Panels A and B plot the geometric mean ratio of egg\u2010grown to cell\u2010grown virus titers one month post\u2010vaccination with 95% confidence intervals, with horizontal bars indicating statistically significant differences. Panels C and D show the proportion of participants with a \u22654\u2010fold reduction in titer to cell\u2010grown virus from pre\u2010 to one month post\u2010vaccination, with p\u2010values for changes in each vaccine group. RIV4 consistently has the lowest egg/cell ratio and shows a significant drop in the proportion with reduced cell\u2010virus titers. Evidence: RIV4 group exhibits significantly lower geometric mean egg/cell titer ratios for A(H3N2) compared to egg\u2010based vaccines and a significant reduction in the proportion of participants with \u22654\u2010fold reduced titer to cell vaccine virus (e.g., 58% pre vs. 26% post in 18\u201344 years, p=0.0001). The data show that the recombinant vaccine (RIV4) elicits antibodies with less bias toward egg-grown epitopes and greater reactivity to cell-grown virus, consistent with broader immune responses; this supports the claim Note: These are serologic surrogate endpoints rather than direct measures of clinical cross-protection in a mismatch season; interpretation is limited to immune\u2010response markers",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "Four\u2010panel figure showing serologic comparisons among four influenza vaccines (Fluzone IIV4, Fluarix IIV4, ccIIV4, RIV4) in two age groups (18\u201344 years in panels A and C, 45\u201364 years in panels B and D). Panels A and B plot the geometric mean ratio of egg\u2010grown to cell\u2010grown virus titers one month post\u2010vaccination with 95% confidence intervals, with horizontal bars indicating statistically significant differences. Panels C and D show the proportion of participants with a \u22654\u2010fold reduction in titer to cell\u2010grown virus from pre\u2010 to one month post\u2010vaccination, with p\u2010values for changes in each vaccine group. RIV4 consistently has the lowest egg/cell ratio and shows a significant drop in the proportion with reduced cell\u2010virus titers.",
        "evidence_found": "RIV4 group exhibits significantly lower geometric mean egg/cell titer ratios for A(H3N2) compared to egg\u2010based vaccines and a significant reduction in the proportion of participants with \u22654\u2010fold reduced titer to cell vaccine virus (e.g., 58% pre vs. 26% post in 18\u201344 years, p=0.0001).",
        "reasoning": "The data show that the recombinant vaccine (RIV4) elicits antibodies with less bias toward egg-grown epitopes and greater reactivity to cell-grown virus, consistent with broader immune responses; this supports the claim",
        "confidence_notes": "These are serologic surrogate endpoints rather than direct measures of clinical cross-protection in a mismatch season; interpretation is limited to immune\u2010response markers"
      }
    },
    {
      "image_filename": "figure_p8_mrg_det_7_005.png",
      "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p8_mrg_det_7_005.png",
      "image_type": "Figure",
      "page_number": 8,
      "block_id": "mrg_det_7_005",
      "claim_id": "claim_003",
      "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
      "supports_claim": true,
      "explanation": "Multi\u2010panel figure showing hemagglutination inhibition (HI) antibody titers (log2 scale) at Day 0 and 1 month post\u2013year-2 vaccination for four influenza viruses (A(H3N2), A(H1N1)pdm09, B/Victoria, B/Yamagata). Each panel displays geometric mean titers with 95% confidence intervals for seven repeat vaccination arms (cell-culture quadrivalent [ccIIV4], recombinant quadrivalent [RIV4], and egg-based quadrivalent [IIV4] in various sequences). Colored horizontal bars denote statistically significant differences (p-values) between the IIV4\u2013IIV4 arm and other arms against cell-propagated viruses. Evidence: RIV4-containing arms (both RIV4\u2013RIV4 and mixed RIV4 sequences) show significantly higher HI GMTs to A(H3N2) cell-propagated virus at 1 month compared with the egg-based IIV4\u2013IIV4 arm (p<0.0001, p=0.013, etc.). The figure supports the claim by demonstrating that recombinant vaccine arms elicit higher antibody titers to cell-propagated (i.e., mismatched) A(H3N2) virus compared with egg-based vaccination, indicating a broader immune response and potential cross-protection. Note: Some labels and small-print details are difficult to read; data shown are immunogenicity (HI titers) rather than direct clinical protection.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "Multi\u2010panel figure showing hemagglutination inhibition (HI) antibody titers (log2 scale) at Day 0 and 1 month post\u2013year-2 vaccination for four influenza viruses (A(H3N2), A(H1N1)pdm09, B/Victoria, B/Yamagata). Each panel displays geometric mean titers with 95% confidence intervals for seven repeat vaccination arms (cell-culture quadrivalent [ccIIV4], recombinant quadrivalent [RIV4], and egg-based quadrivalent [IIV4] in various sequences). Colored horizontal bars denote statistically significant differences (p-values) between the IIV4\u2013IIV4 arm and other arms against cell-propagated viruses.",
        "evidence_found": "RIV4-containing arms (both RIV4\u2013RIV4 and mixed RIV4 sequences) show significantly higher HI GMTs to A(H3N2) cell-propagated virus at 1 month compared with the egg-based IIV4\u2013IIV4 arm (p<0.0001, p=0.013, etc.).",
        "reasoning": "The figure supports the claim by demonstrating that recombinant vaccine arms elicit higher antibody titers to cell-propagated (i.e., mismatched) A(H3N2) virus compared with egg-based vaccination, indicating a broader immune response and potential cross-protection.",
        "confidence_notes": "Some labels and small-print details are difficult to read; data shown are immunogenicity (HI titers) rather than direct clinical protection."
      }
    }
  ]
}